When is intervention warranted?

R. D. Williams, D. G. Bostwick, C. W. Boone, W. J. Catalona, W. McKeehan, I. M. Thompson

Research output: Contribution to journalArticle

Abstract

A chemoprevention trial in prostate cancer would be a formidable but potentially rewarding study. The current status of knowledge of drug interactions with, biomarkers of, and even the natural history of prostate cancer is insufficient to study all levels of men at risk. Currently, the most promising group to study is group I--those men with a high probability of developing prostate cancer but who do not currently have evidence of the disease. This could be a placebo-controlled, prospective and randomized study with the endpoint being clinically-detected prostate cancer. In addition, much may be gained from short-term pilot studies of "chemo-active" agents on morphologic and other biomarkers of prostate cancer initiated immediately before surgical removal. It is hoped that such studies may provide rationale for future efforts directed at preventing progression of premalignant or early prostate cancer lesions.

Original languageEnglish (US)
Pages (from-to)138-139
Number of pages2
JournalJournal of cellular biochemistry. Supplement
Volume16 H
StatePublished - 1992
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Biomarkers
Chemoprevention
Drug Interactions
Placebos
Prospective Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Williams, R. D., Bostwick, D. G., Boone, C. W., Catalona, W. J., McKeehan, W., & Thompson, I. M. (1992). When is intervention warranted? Journal of cellular biochemistry. Supplement, 16 H, 138-139.

When is intervention warranted? / Williams, R. D.; Bostwick, D. G.; Boone, C. W.; Catalona, W. J.; McKeehan, W.; Thompson, I. M.

In: Journal of cellular biochemistry. Supplement, Vol. 16 H, 1992, p. 138-139.

Research output: Contribution to journalArticle

Williams, RD, Bostwick, DG, Boone, CW, Catalona, WJ, McKeehan, W & Thompson, IM 1992, 'When is intervention warranted?', Journal of cellular biochemistry. Supplement, vol. 16 H, pp. 138-139.
Williams RD, Bostwick DG, Boone CW, Catalona WJ, McKeehan W, Thompson IM. When is intervention warranted? Journal of cellular biochemistry. Supplement. 1992;16 H:138-139.
Williams, R. D. ; Bostwick, D. G. ; Boone, C. W. ; Catalona, W. J. ; McKeehan, W. ; Thompson, I. M. / When is intervention warranted?. In: Journal of cellular biochemistry. Supplement. 1992 ; Vol. 16 H. pp. 138-139.
@article{94df8860187a4dc2a30e92f5174c03d1,
title = "When is intervention warranted?",
abstract = "A chemoprevention trial in prostate cancer would be a formidable but potentially rewarding study. The current status of knowledge of drug interactions with, biomarkers of, and even the natural history of prostate cancer is insufficient to study all levels of men at risk. Currently, the most promising group to study is group I--those men with a high probability of developing prostate cancer but who do not currently have evidence of the disease. This could be a placebo-controlled, prospective and randomized study with the endpoint being clinically-detected prostate cancer. In addition, much may be gained from short-term pilot studies of {"}chemo-active{"} agents on morphologic and other biomarkers of prostate cancer initiated immediately before surgical removal. It is hoped that such studies may provide rationale for future efforts directed at preventing progression of premalignant or early prostate cancer lesions.",
author = "Williams, {R. D.} and Bostwick, {D. G.} and Boone, {C. W.} and Catalona, {W. J.} and W. McKeehan and Thompson, {I. M.}",
year = "1992",
language = "English (US)",
volume = "16 H",
pages = "138--139",
journal = "Journal of cellular biochemistry. Supplement",
issn = "0733-1959",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - When is intervention warranted?

AU - Williams, R. D.

AU - Bostwick, D. G.

AU - Boone, C. W.

AU - Catalona, W. J.

AU - McKeehan, W.

AU - Thompson, I. M.

PY - 1992

Y1 - 1992

N2 - A chemoprevention trial in prostate cancer would be a formidable but potentially rewarding study. The current status of knowledge of drug interactions with, biomarkers of, and even the natural history of prostate cancer is insufficient to study all levels of men at risk. Currently, the most promising group to study is group I--those men with a high probability of developing prostate cancer but who do not currently have evidence of the disease. This could be a placebo-controlled, prospective and randomized study with the endpoint being clinically-detected prostate cancer. In addition, much may be gained from short-term pilot studies of "chemo-active" agents on morphologic and other biomarkers of prostate cancer initiated immediately before surgical removal. It is hoped that such studies may provide rationale for future efforts directed at preventing progression of premalignant or early prostate cancer lesions.

AB - A chemoprevention trial in prostate cancer would be a formidable but potentially rewarding study. The current status of knowledge of drug interactions with, biomarkers of, and even the natural history of prostate cancer is insufficient to study all levels of men at risk. Currently, the most promising group to study is group I--those men with a high probability of developing prostate cancer but who do not currently have evidence of the disease. This could be a placebo-controlled, prospective and randomized study with the endpoint being clinically-detected prostate cancer. In addition, much may be gained from short-term pilot studies of "chemo-active" agents on morphologic and other biomarkers of prostate cancer initiated immediately before surgical removal. It is hoped that such studies may provide rationale for future efforts directed at preventing progression of premalignant or early prostate cancer lesions.

UR - http://www.scopus.com/inward/record.url?scp=0027023106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027023106&partnerID=8YFLogxK

M3 - Article

VL - 16 H

SP - 138

EP - 139

JO - Journal of cellular biochemistry. Supplement

JF - Journal of cellular biochemistry. Supplement

SN - 0733-1959

ER -